DGAP-News: Brenntag AG / Key word(s): Corporate Action Implementation of Brenntag AG stock split on August 1, 2014 24.07.2014 / 14:40 --------------------------------------------------------------------- Mülheim an der Ruhr, July 24, 2014 Implementation of Brenntag AG stock split on August 1, 2014 - 1:3 stock split on August 1, 2014 - Shares in securities accounts will be converted automatically by the depository banks Brenntag, the global market leader in chemical distribution, will proceed with a 1:3 stock split on August 1, 2014, as resolved by the General Shareholders' Meeting on June 17, 2014. On that date, the quotation of Brenntag shares (WKN A1DAHH, ISIN DE000 A1DAHH) in the Frankfurt Stock Exchange regulated market (Prime Standard) will be converted without the securities identification number being changed. "Since being listed at the stock exchange in March 2010, the Brenntag share price has shown a very pleasing performance. The absolute share price now looks relatively high compared to the prices of other MDAX shares. The stock split is intended to make our shares more attractive to an even wider range of investors and to increase the share's liquidity," says Georg Müller, Brenntag AG's Chief Financial Officer, explaining the move. Following the capital increase from company funds through the issue of new shares, the registered share capital of the company is now EUR 154,500,000 and is divided into an equally high number of registered no-par-value shares following the split. Shareholders will be issued two additional shares for each Brenntag share they hold by their depository bank. The change does not require any action from them. The share price will also be arithmetically divided by three without having an impact on the value of each shareholder's portfolio. About Brenntag: Brenntag, the global market leader in chemical distribution, covers all major markets with its extensive product and service portfolio. Headquartered in Mülheim an der Ruhr, Germany, the company operates a global network with more than 480 locations in more than 70 countries. In 2013, the company, which has a global workforce of more than 13,000, generated sales of EUR 9.8 billion (USD 13.0 billion). Brenntag is the link between chemical manufacturers and chemical users. The company supports its customers and suppliers with tailor-made distribution solutions for industrial and specialty chemicals. With over 10,000 products and a world-class supplier base, Brenntag offers one-stop-shop solutions to around 170,000 customers. This includes specific application technology, an extensive technical support and value-added services such as just-in-time delivery, product mixing, formulation, repackaging, inventory management and drum return handling. Long-standing experience and local excellence in the individual countries characterize the global market leader in chemical distribution. Press contact:: Hubertus Spethmann Brenntag AG Corporate Communications Stinnes-Platz 1 45472 Mülheim an der Ruhr Germany Tel: +49 (208) 7828-7701 Fax: +49 (208) 7828-7220 E-mail: hubertus.spethmann@brenntag.de http://www.brenntag.com Contact for investors: Thomas Langer, Diana Alester, René Weinberg Brenntag AG Corporate Finance & Investor Relations Stinnes-Platz 1 45472 Mülheim an der Ruhr Germany Tel: +49 (208) 7828-7653 Fax: +49 (208) 7828-7755 E-mail: IR@brenntag.de http://www.brenntag.com End of Corporate News --------------------------------------------------------------------- 24.07.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Brenntag AG Stinnes Platz 1 45472 Mülheim an der Ruhr Germany Phone: +49 (0) 208 7828 - 7653 Fax: +49 (0) 208 7828 - 7755 E-mail: ir@brenntag.de Internet: www.brenntag.com ISIN: DE000A1DAHH0 WKN: A1DAHH Indices: MDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 279251 24.07.2014
DGAP-News: Implementation of Brenntag AG stock split on
Top 10 Most Recent News Articles
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
Princess Cruises Launches New Era at Celebration Key
Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
Berry Street Integrates AI with What Matters: Human Touch
Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...
Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market
Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...
Continue ReadingTop 5 Most Recently Viewed Articles
Innovative Scent Dispensing Solution for Hunting Enthusiasts
Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...
Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results
Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...
Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices
Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...
Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today
Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...
Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates
Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...
Continue Reading